New biotech Roxiant to tackle age-related diseases
Pharmacosmos heir Andreas Christensen, who recently founded the biotech company Roxiant, will use a protein found in people who live for an exceptionally long time to treat age-related diseases, and its first target is Huntington's disease.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN
Andreas Christensen flew the nest last year, leaving Pharmacosmos, which was founded by his paternal grandfather Henry Christensen and is still run by the family, to start biotech firm Roxiant.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos launches cell therapy market offensive
For subscribers
